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Glomerular up-regulation of EllA and V120 fibronectin isoforms in
proliferative immune complex nephritis. Fibronectins (FNs) comprise a
family of adhesive glycoproteins that are prominent components of
mesangial extracellular matrix and accumulate during glonierular injury.
By alternative splicing of an unique mRNA precursor, various FN
isoforms can be originated. In rat, three regions of the molecule are
involved: EIIIA, EIIIB and V. Because specific FN isoforms are expressed
in embryogenesis and wound healing, conditions characterized by cell
migration and adhesion, we examined the pattern of FN isoforms in the
mild and severe phases of a progressive immune complex proliferative
nephritis in rats. We constructed specific probes to analyze the splicing
pattern of FN pre-mRNAs by ribonuclease protection assays. FN mRNAs
containing EI1IA, EHIB and V regions increased along the progression of
nephritis, though the increment of EIIIB-FN mRNA was modest. How-
ever, different regulation of all these isoforms was observed. The percent-
age of FN mRNA containing the EIIIA exon versus total FN increased
with the severity of the disease, while the percentage of FN mRNA
containing the EIIIB exon decreased. Relative V-FN mRNA expression
versus total FN mRNA increased only in the severe phase. By means of
specific antibodies we also studied the presence of EIIIA, EII1B and V-FN
proteins in the kidney. in the normal glomerulus, EIIIA-FN protein was
barely detectable in the mesangium, increasing in the mild phase of
nephritis. In the severe phase of nephritis, increased EIIIA-FN was
localized in the mesangiurn, in Bowman's capsule and in crescents. By
contrast, EIIIB-FN protein in the glomerulus was absent even in the
severe phase. V120-FN protein, an isoform that mediates the attachment
of leukocytes through the VLA-4 integrin, was present in the mesangium
and glomerular capillary loops in control animals, and increased in the
severe phase of nephritis, coinciding with a strong leukocyte infiltration, In
conclusion, our results show that during immune glomerular injury there
were marked changes in the pattern of FN isoforms expression. Since
those isoforms, particularly V120 isoform, are important in cell adhesion
and migration, their up-regulation may facilitate the recruitment of cells
into the injured glomeruli. The blockade of the interaction between
V120-FN and infiltrating leukocytes may represent a new approach to the
treatment of nephritis.
Fibronectins (FNs) are major components of the extracellular
matrix in the mesangium. They are high molecular weight glyco-
proteins playing important roles in cell adhesion, differentiation,
migration and thus in embryogenesis, wound repair, hemostasis,
and thrombosis [1].
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The primary structure of FN is composed of three different
kinds of repeated sequences, known as types I, II, and III with a
characteristic modular structure. These repeats are assembled
into a series of structural domains, each having a distinct binding
activity to other extracellular matrix proteins and cell surface
receptors (Fig. 1A).
There are several forms of FN which differ in their primary
structure by the alternative splicing of an unique mRNA precur-
sor (pre-mRNA) transcribed from a single gene [2, 31. Three sites
of alternative splicing have so far been described: ED-A, ED-B
and IIICS in human FN and the corresponding regions EII1A,
EII1B and V in rat FN. EII1A and EIIIB are type III repeats,
flanking the exon containing the RGDS sequence that mediates
cell adhesion by interactions with the FN receptor VLA-5. These
sequences could be either omitted or included in the mature
mRNA (Fig. 1B) and are always absent in plasma FN, primarily
synthesized by the liver. However, EI1IA and EIIIB are identified
in mRNA from fibroblasts, several other cells and tissues. Thus,
EIIIA and EII1B sequences codii' for unique domains of cellular
FN. The third alternatively spliced exon (V, variable region) has
no homology with types I, II and III repeats. The V region in rat
may be partially or completely excluded, depending on the
splicing site used, and may generate inserts of 0, 95 or 120 amino
acids (Fig. 1B) [41.
Although the functions of the EI1IA and EII1B domains are
unknown, their localization adjacent to the central cell binding
region suggests some role in cell adhesion and migration [4—6].
The V region contains at least one cell-binding site in the first
25 amino acids included in the V120 isoform, which is a ligand for
the VLA-4 integrin present in mononuclear cells, and therefore
suggesting that splicing within this domain may alter cell-specific
FN attachment [7, 8].
The alternative splicing of FN pre-mRNA is regulated in a cell-,
tissue-, and developmentally-specific manner and in response to
growth factors [9—12]. During tissue injury, as wound healing [13],
intimal vascular thickening [14] or cardiac hypertrophy [15, 16],
there are modifications in the pattern of FN isoforms expression.
While the increase in total glomerular FN has been well
characterized in nephritis [17], the composition of FN isoforms in
the normal and injured kidney remains largely unknown. The
pattern of FN isoforms in the normal fetal and adult kidney has
been recently described by immunohistochemical techniques [18].
EIIIA-FN and EIIIB-FN were expressed in the developing
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EIIIA and
EIIIB V
nephron, while in the adult human kidney only EIIIA-FN was
noted in the mesangium. Recently, Assad and coworkers de-
scribed the immunolocalization of EIIIA-FN and EIIIB-FN in
diverse glomerulopathies [19]. However, the splicing pattern of
FN isoforms EI1IA, EII1B and V during glomerular damage has
not been studied.
In an experimental model of immune complex nephritis in rats
we have characterized the expression and localization of EN
isoforms in the mild and severe phases of the disease. Our data
indicate that specific FN isoforms are expressed during glomeru-
lar injury, in part as a consequence of alterations in the alternative
splicing of FN pre-mRNAs. Furthermore, we report for the first
time the expression of V120-FN in nephritis. The potential
interaction between the V120-FN and infiltrating mononuclear
cells through VLA-4 integrin could represent a target in the
treatment of nephritis.
Methods
Model of immune complex nephritis in rat
Inbred female Wistar rats weighing 200 to 220 g were obtained
from the FundaciOn Jimnez DIaz animal facilities. Immune
complex glomcrulonephritis was induced in rats previously immu-
nized with ovaihumin (Sigma Chemical Co., St. Louis, MO, USA)
by daily administration of 10 mg ovalbumin [20]. The studies were
performed in two different phases of the disease: mild (5 to 10
mg/day proteinuria, mesangial immune complex deposits and
absence of cell infiltration) and severe (nephrotic syndrome,
immune complex deposits in mesangium and capillary wall, and
strong cell infiltration). The two phases occurred around the 4 to
Fig. 1. A. Diagram of a FN subunit. The
structure of FN is composed by a series of
repeats named types I, II and III. Sets of
repeats that comprise binding domains with
affinities for fibrin, heparin, proteoglycans,
collagen, and integrin receptors are shown. The
alternatively spliced exons EI1IA and EII1B are
striped. The V region is also alternatively
spliced and is shown as a rectangle with closed
(V25, which contains the binding site to VLA-4
integrin) and striped (V95) areas. B.
Alternative splicing of FN pre-mRNA. During
splicing of the FN pre-mRNA the EI1IA and
EIIIB exons may be either included or excluded
to give the final products shown in the scheme.
Alternative splicing of the V region in the rat
generates three isoforms named V120
(containing the entire V region and the binding
site to VLA-4), V95 (lacking the first 25
aminoacides) and VO (lacking the entire V
region) [1, 4].
5th week and the 7 to 8th week after i.p. ovalbumin administra-
tion, respectively. At the moment of sacrifice, blood was drawn
and kidneys were removed. Cholesterol, triglycerides, serum
albumin and serum and urine creatinine were measured by a
standard autoanalyzer.
Renal histopathological studies
For conventional light microscopy, renal tissue was fixed in
buffered formalin and embedded in paraffin. Sections (2 to 3 xm
thick) were prepared and stained with hematoxylin and eosin, and
Masson trichrome. For immunohistochemistry the specimens
were embedded in OCT. (Miles Inc., Elkhart, IN, USA), snap
frozen and stored at —70°C until sections were cut (6 xm).
Immunolocalization of total FN (all FN isoforms) was per-
formed with a polyclonal antibody against rat plasma FN raised in
rabbits [21], EIIIA-FN with IST-9 MoAb [221 (Seralab, Sussex,
UK), EIIIB-FN with BC-i MoAb (provided by Dr. L. Zardi) [23]
and V120-FN with 90.45 MoAb (provided by Dr. Mi. Elices) [241.
Fluorescein-conjugated sheep F(ab')2 anti-rabbit and horseradish
peroxidase-conjugated sheep F(ab')2 anti-mouse immunoglobu-
lins were used as secondary antibodies (Amersham Ibérica,
Madrid, Spain). The peroxidase-catalyzed reaction was developed
with 0.5 mg/mI diaminobenzidine (DAB) and 0.02% hydrogen
peroxide. Negative controls were provided by omitting the pri-
mary antibody or by replacing it by an irrelevant antibody of the
same isotype.
Immunostaining was graded as: —, non-staining; traces; +,
mild; ++, moderate and +++, intense. The localization of the
reaction was referred as mesangial, peripheral capillary loop and
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Fig. 2. Specificity of riboprobes used in ribonuclease protection assays. TenjLg of total RNA from NRK-49F cells (normal rat kidney fibroblasts,
ATCC CRL-1570) and/or liver RNA were hybridized with EIIIA, EII1B,
and V specific riboprobes. After degradation of RNA:RNA hybrids with
ribonucleases the protected fragments were separated in a gel giving the
pattern shown in the figure. When hybridization was performed with
Elif A (A) and EII1B (B) riboprobes, RNA from cells gave two protected
fragments corresponding to mRNA including (EIIIA+ and EIIIB+
mRNA) or excluding (EI1IA— and EII1B— mRNA) the alternatively
spliced exon. By contrast, the RNA from liver lacks the EI1IA and EII1B
exons [1, 4]. (C) When hybridization was performed with V riboprobe on
liver RNA, three bands corresponding to the three possible variants could
be observed (V120, V95 and VO). In liver, as in other tissues, the three
isoforms are usually produced [1, 4] although in different proportions.
MW: RNA molecular weight (indicated in bases) produced by in vitro
transcription (Ambion, Austin, TX, USA), probe: undigested probe,
tRNA: negative control, yeast transfer RNA. On the right of each Figure
a scheme of the protected fragments and their corresponding mRNAs are
shown.
Bowman's capsule. Reactions occurring in other localizations
were recorded accordingly.
The quantification of the glomerular infiltrating mononuclear cells
was performed as previously published [25]. The MoAb employed
were the following: OXI (leukocyte common antigen [26]), W3/13 (T
lymphocytes [27]) (Seralab, Sussex, UK) and ED1 (monocytes/
macrophages [28]) (Serotec, Oxford, UK). Only cells with a nucleus
that could be clearly identified were counted. Twenty glomeruli from
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Table 1. Biochemical data of the mild and severe phases of nephritis
Groups
Control Mild phase Severe phase
Proteinuria 2 1 8 1 341 45°
mg/dl
Triglycerides 39 6 47 4 352 87°
mg/dl
Cholesterol 72 6 73 6 246 30k'
mg/dl
Serum albumin 3.6 0.1 3.5 0.1 1.8 0.1°
gidi
Cr 386 21 380 14 293 20k'
p1/mini] 00 g
Results are expressed as mean SEM of 10 animals for each group.
Abbreviation is C, creatinine clearance.
P < 0.05 vs. Control.
two sections of each animal were counted and the results expressed
as number of positive cells per glomeruli cross-section.
All histological studies were performed without the observer
knowing to which group the animals belonged (double blind
study).
Glomerular RNA isolation and Northern blot analysis
Glomeruli were isolated by differential sieving according to a
previously published technique [29]. All steps were performed at
4°C. Total glomerular RNA was obtained by the acid guanidine-
thiocyanate-phenol-chioroform method [30]. The concentration
and purity of the samples were determined by spectrophotometry.
RNA was denatured and fractionated by electrophoresis through
an 1.2% agarose-formaldehyde gel (25 jig/lane) and blotted to a
nylon membrane (Dupont, Boston, MA, USA). Membranes were
prehybridized for six hours at 42°C with 50% formamide, 1%
SDS, 5 x SSC, lx Denhardt's solution, 250 jxg/ml denatured
herring sperm DNA and 50 m phosphates, pH 6.5. The hybrid-
ization was performed for 18 to 20 hours at 42°C in the same
solution with 10% dextran sulphate and DNA probes labeled with
a[32P]-dCTP (Dupont) by random oligonucleotide priming. DNA
probes were a 270 nt fibronectin eDNA fragment from pSR27O
[13], kindly provided by Dr. R.O. Hynes, and a 1.5 Kb rRNA 28S
eDNA fragment as a control for loading. The membranes were
exposed to X-OMAT films (Eastman Kodak Co., Rochester, NY,
USA) and the autoradiograms scanned by bidimensional laser
densitometry, using a densitometer (Molecular Dynamics, Sunny-
vale, CA, USA).
Probe preparation for rihonuclease protection assay
To study the alternative splicing of EN pre-mRNA we con-
structed specific probes for the ETIIA, EII1B and V regions.
Standard methods were used, when not otherwise detailed [31].
Reverse transcription-polymerase chain reactions (RT-PCR).
Three sets of oligonucleotide DNA primers complementary to the
sequence of rat FN (EMBL X15906) with 5' terminal recognition
Sites for restriction enzymes were purchased from Biosynthesis
(Fuenlabrada, Spain). The sequences were as below:
EI1IAI (sense) - 5' GGA AGC YI'G ACC GCC CTA AAG
GAC TGG -3'
EIIIA2 (antisense) -5' GGG ATC CTT AAC ACT GGG CGC
TGT CC -3'
EI1IB1 (sense) - 5' GGG AAT TCA AGC ATC GGC CTG
AGG T -3'
EIIIB2 (antisense) -5' GGA AGC TIC CTC CTC GTT CTT
CAC AGG -3'
Vi (sense) - 5' GGG GAT CCC CAA CTG GY17 ACC CTf
CC -3'
V2 (antisense) - 5' GGA AGC TIC CAG TCA GAG TCG
CAC TGG -3'
The primers spanned the following parts of the FN gene: from
nt 5372 (located in the EII1A exon) to nt 5721 (in 111-12), from nt
4045 (in EII1B) to nt 4406 (in 111-8) and from nt 6459 (in V) to nt
6959 (in 111-15).
The synthesis of eDNA was carried out in a 50 pl reaction
volume containing I jig RNA from whole kidney, 1.25 mrvi dNTPs,
1xPCR buffer (Perkin-Elmer Cetus Corp., Norwalk, CT, USA)
13.75 ng random primers, 40 U RNasin (Promega Biotec, Madi-
son, WI, USA) and 25 U AMV reverse transcriptase (Promega
Biotec) incubated for 30 minutes at 42°C. Ten jil of this mixture
were included in a 100 jrl volume reaction with 50 pmol of each
corresponding set of primers, 0.2 m of each dNTP and 2.5 U Taq
polymerase (Perkin-Elmer Cetus Corp.), and subjected to 25
cycles of PCR each consisting of one minute at 94°C, two minutes
at 60°C and three minutes at 72°C.
Cloning. The amplified fragments (362 bp, 375 bp and 514 bp
for EII1A, EIIIB and V, respectively) were analyzed by electro-
phoresis on agarose gels, subjected to restriction endonuclease
digestion (HindIII/BamHI for EIIIA and V, and EcoRI!HindIII
for EIIIB) and cloned in pGEM4Z (Promega Biotec). Clones
were sequenced by the dideoxi-termination chain method (Seque-
nase, USB, Cleveland, OH, USA). The nucleotide sequences of
these clones were identical to the previously reported rat FN
sequence (EMBL X15906).
Ribonuclease protection analysis
Single-strand antisense RNA probes, labeled with cs[32P]-CTP
(Dupont) to a specific activity of iO cpm/jxg, were synthesized
from linearized plasmids using SP6 or T7 RNA polymerases
(Promega Biotec). Approximately 106 cpm of probe were hybrid-
ized overnight at 52°C with 20 to 25 jig of total RNA in 30 jil of
80% formamide, 40 m Pipes (pH 6.4), 400 mrvi NaC1 and 1 mM
EDTA. An additional control with yeast transfer RNA (tRNA)
was included in each assay. Unhybridized RNA was digested for
90 minutes at 30°C in 300 pd RNase solution (300 mrvi NaC1, 5 mM
EDTA, 700 U/mI RNase Ti (Gibco-BRL) and 40 jig/mI RNase A
(Boehringer, Mannheim, Germany) 10 mivi Tris-HCI pH 7.4).
Then, 10 j.tl SDS (20% wt/vol) and 2.5 pd proteinase K (20 mg/mI)
were added to each sample and incubated for 20 minutes at 37°C
to remove nucleases. The mixture was extracted with phenol!
chloroform/isoamyl alcohol and precipitated with ethanol. The
protected fragments were analyzed on 6% denaturing polyacryl-
amide gels and by subsequent autoradiography with X-OMAT
film (Eastman Kodak Co.). As shown in Figure 2A and 2B, EIIIA
and EIIIB riboprobes detected FN mRNAs containing (isoform
+) and lacking (isoform —) the alternatively spliced exon in total
RNA from NRK-49F cells (normal rat kidney fibroblasts, ATCC
CRL-1570), but only the negative isoform was detected in total
RNA from liver [1, 4]. The V riboprobe (Fig. 2C) detected the
V120, V95 and VO isoforms in total RNA from liver. These results
coincided with previous reports [1, 4] and demonstrated the
specificity of the constructed probes.
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Fig. 3. Model of immune complex proliferative nephritis. Representative glomeruli from mild (A) and severe (B) phases stained with fluorescein-
conjugated anti-rat lgG. In this model of proliferative nephritis, immune deposits are initially restricted to the mesangium in the mild phase (A)
Thereafter, in the severe phase, immune deposits extend to the glomerular capillary wall (B). Histology of representative glomeruli from control (C),
mild (D) and severe phases (E, F). Rats in the mild phase presented a slight increase in mesangial extraecllular matrix (D). In the severe phase, animals
developed marked glomerular hypercellularity and extracellular matrix expansion (E) and crescentic lesions (F). A and B, direct immunofluoreseence
x1{JO; C-E, Masson trichrome XiOO; F, Hematoxylin and eosin XlOO.
To quantify the relative amounts of FN mRNA containing a containing the alternatively spliced exons were larger than those
particular isoform, the protected RNA fragments were scanned by lacking them, the relative intensity of the bands lacking the
bidimensional laser densitometry. Since the protected fragments alternatively spliced exons was corrected to take into account the
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Fig. 4. Northern blot analysis of glomerular RNA from control rats and rats
with nephritis. (A) Each lane contains 30 ig of a pool (4 to 6 animals) of
total glomerular RNA from the designated groups. The same nylon
membrane was hybridized with a FM eDNA probe (which recognizes all
FN mRNA isoforms) and rehybridized with the 28S eDNA probe as a
control for loading. (B) Quantitation of the FN mRNA bands by laser
densitometry, normalized to the respective 28S rRNA bands. Data are the
mean of two similar experiments. The individual data were 2.5- and
3.2-fold-increase in the mild phase and 5.9- and 5.7-fold in the severe
phase of nephritis.
Fig. 5. Alternative splicing of EJIJA exon in immune complex proliferative
nephritis. Total glomerular RNA (30 rg) was allowed to hybridize with the
32P-labeled EJIIA riboprobe covering a portion of the ETTIA exon and a
portion of an adjacent exon nonalternatively spliced. After digestion with
ribonucleases, the protected fragments were separated by electrophoresis.
The gel was dried and exposed to X-ray film, and the intensity of the bands
was quantitated by laser densitometiy. The positions of FN mRNA
containing the EllA exon (EIIIA+) and lacking it (EII1A—) are indi-
cated (see Methods and Fig. 2 for details). (A) lane 1, undigested probe;
lane 2, 30 .eg of yeast tRNA (negative control); lanes 3, control rats; lanes
4, rats with mild nephritis; lanes 5, rats with severe nephritis. Each lane
represents a different animal from the corresponding group. (B) Relative
FN-EJIIA+ mRNA levels with respect to total FM mRNA in the different
groups. Data are expressed as mean SEM. Asterisk (*) indicates a
significant (P < 0.05) shift in the alternative splicing pattern in the severe
phase with respect to control animals. Representative of two experiments.
size difference, assuming that an equal rate of a[32P]-CTP incor-
poration occurred for all protected fragments. The data are
expressed as the percentage of the mRNAs containing the alter-
natively spliced exon versus the total of FN mRNAs (the sum of
the mRNAs containing and lacking the alternatively spliced
exons).
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among groups were examined using the ANOVA test. A P
value < 0.05 was considered statistically significant.
Results
Evolution of disease
In the mild phase of nephritis, the clinical parameters were in
the normal range, except a slight increase in proteinuria (Table 1).
Immune deposits were restricted to the mesangium, and the glomer-
ular cellularity was normal though a slight increase in the mesangial
matrix could be noted (Fig. 3). By contrast, in the severe phase of
nephritis, proteinuria was strongly elevated and progressed to a
full-blown nephrotic syndrome (Table 1). At this time immune
deposits were present in the mesangium and also in the peripheral
capillary ioops. There were glomerular hypercellularity and cellu-
lar infiltration, intense mesangial matrix expansion, and some
crescents (Fig. 3).
FN isoforms expression
Fig. 6. Alternative splicing of EIIIB exon in immune complex proliferative
nephritis. Ribonuclease protection assay was performed as described in
Figure 5, except that the riboprobc covered a portion of the EIIIB exon
and also a portion of an adjacent exon nonatternatively spliced. The
positions of FN mRNA containing the FluB exon (EHIB+) and lacking
it (FluB—) are indicated (see Methods and Fig. 2 for details). (A) lane 1,
undigested probe; lane 2, 30 rg of yeast tRNA (negative control); lanes 3,
control rats; lanes 4, rats with mild nephritis; lanes 5, rats with severe
nephritis. Each lane represents a different animal from the corresponding
group. (B) Relative FN-EIIIB+ mRNA levels with respect to total FN
mRNA in the different groups. Data are expressed as mean SEM.
Asterisk (*) indicates a significant (P < 0.05) shift in the alternative
splicing pattern in the mild and severe phase with respect to control
animals. Representative of two experiments.
Statistical analysis
GraphPAD Instat software (GraphPAD software, San Diego,
CA, USA) was used for statistical determinations. Differences
Total FN. By Northern blot we analyzed the FN mRNA
steady-state levels in glomeruli of rats with nephritis. In compar-
ison to control animals, rats with mild nephritis, but chiefly with
severe nephritis, showed a clear increase in the steady-state FN
mRNA levels (3- and 6-fold increase vs. control animals, respec-
tively; Fig. 4).
EIIL4-FN. Alternative splicing at EI1IA exon generates two
types of FN mRNA that differ in terms of the presence or the
absence of the EIIIA sequence. The two FN mRNA variants,
EIIIA+ (with EII1A exon) and EII1A- (without EI1IA exon) and
the fragments protected by the probe used in the ribonuclease
protection assay are shown schematically in Figures 1 and 2.
Total glomerular RNA from control rats and rats with nephritis
was analyzed by rihonuclease protection assay using the EI1IA
probe. Representative data are shown in Figure 5.
Consistent with the findings by Northern blot analysis, glomer-
ular RNA from rats with mild and severe nephritis contained
more mRNA for all FN isoforms (observed thereafter with the
EII1B and V probes; Fig. 5A). Densitometric analysis indicated
that EIIIA-containing FN mRNA (EIIIA+) increased over con-
trol around fourfold in rats with mild nephritis and sevenfold in
rats with severe nephritis. FN mRNA lacking the EII1A domain
(EI1IA—) was also increased in both phases of nephritis, with
values around threefold and fivefold, respectively, above controls.
As a consequence, the relative expression of EIIIA+ FN mRNA
versus total FN mRNA increased from 43 3% in control rats to
52 2% and 57 7% in the mild and severe phases, respectively
(P < 0.05 severe phase vs. control animals; Fig. SB).
EIIIB-FN. Like EllIA, the alternative splicing at the EII1B exon
generates two types of FN mRNAs (Figs. I and 2). Figure 6 shows
representative data for ribonuclease protection assay performed
with total glomerular RNA from rats in different phases of the
disease using the EII1B probe. EII1B-containing FN mRNA
(EIIIB+) increased around twofold in rats with mild and severe
nephritis over healthy controls. In contrast, both in the mild and
severe phases, a strong increase was observed in the expression of
FN mRNA lacking the EII1B exon (EII1B—) around eightfold
and 18-fold over healthy controls (Fig. 6A). As a consequence, the
relative expression of EIIIB+ FN mRNA versus total FN mRNA
decreased from 10 1% in control rats to 5 1% and 2 1%
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Table 2. Immunolocalization of FN isoforms in immune complex
proliferative nephritis
EIIIB-FN V120-FNGroups Total FN EIIIA-FN
Control mes + — +
GCL
— — +
—
— —
—
— +
—
— ++
— +
— +
Total FN, EIIIA-FN, EIIIB-FN and V120-FN were immunostained
with a polyclonal anti-rat plasma FN, and the IST-9, BC-i and 90.45
MoAbs, respectively. At least three animals from each group were
analyzed by two independent observers (double blind study). Staining was
scored as non-staining; traces; +, mild; ++, moderate; +++,
intense. mes, mesangium; GCL, glomerular capillaiy loops; BC, Bowman's
capsule.
Fig. 7. Alternative splicing of V region in immune complex proliferative
nephritis. Ribonuclease protection assay was performed as described in
Figure 5, except that the riboprobe covered the V region and also a
portion of an adjacent exon nonalternatively spliced. On this occasion 30
g of total glomerular RNA from a pool of five to six animals were
analyzed. The positions of FN mRNA containing the V120 and V95
regions are indicated (see Methods and Fig. 2 for details). Because the
high background observed in these experiments made difficult the identi-
fication of the band corresponding to the VO isoform, in this study only
V120 and V95 FN mRNAs were considered for densitometric analysis.
Thus, total FN mRNA is the sum of Vi20 and V95 FN mRNAs. (A) lane
i, undigested probe; lane 2, 30 j.tg of yeast tRNA (negative control); lane
3, control rats; lane 4, rats with mild ncphritis; lane 5, rats with severe
nephritis. (B) Relative V120-FN mRNA levels with respect to total FN
mRNA in the different groups. Data are expressed as mean SEM of a
total of three similar experiments. Asterisk (*) indicates a significant (P <
0.05) shift in the alternative splicing pattern in the severe phase with
respect to control animals.
in the mild and severe phases of nephritis, respectively (P < 0.05
vs. control animals; Fig. 6B).
V-FN. Alternative splicing at the V region can generate three
different isoforms, named V120, V95 and VO in rats, according to
the number of amino acids present in the sequence (Figs. 1 and 2).
The V120 isoform includes the CS-i sequence, which is recog-
nized by the VLA-4 integrin present in leukocytes and which
mediates the attachment of these cells.
The V probe used in this study covers the entire V region and
thus it allows the identification of all three isoforms (Fig. 2).
However, the high background observed in these experiments
made difficult the identification of the band corresponding to the
VO isoform. In some experiments, however, this identification was
possible, without modifying qualitatively the results. Hence, in this
study only V120 and V95 were considered for densitometric
analysis. In this case, the samples used in the ribonuclease
protection assay were pooled from five or six different animals and
thus represent a mean value for each phase timepoint (Fig. 7).
In the mild phase of nephritis, both V95-FN and V120-FN
mRNA increased around twofold above the controls. In the
severe phase, V120-FN mRNA increased 19 times, while V95-FN
mRNA increased 12 times (Fig. 7A). The relative expression of
V120-FN mRNA versus total FN mRNA expression increased
from 37 3% in control rats to 51 1% in the severe phase (P <
0.05; Fig. 7B).
Immunolocalization of FN isoforms
To study by immunohistochemistry the distribution of EN
isoforms along the course of the disease we used a rabbit
polyclonal antibody to rat plasma FN, and a panel of MoAbs
specific to EII1A, EIIIB and V120 isoforms. A summary of the
data of these studies is presented in Table 2.
Total F/V. In normal rats, total FN was detected in the mesan-
gium and interstitium. In the mild phase of nephritis the distri-
bution of FN was similar to normal animals, but the intensity of
the mesangial FN was higher. In the severe phase, glomerular FN
increased in a striking manner in the mesangial area with exten-
sion to the glomerular capillary wall, being also present in
crescents (Fig. 8 A-C).
EIIIA-FN. Using the IST-9 MoAb specific to the EI1IA exon of
cellular FN, we barely detected this isoform in the mesangium of
normal rats. In the mild phase of nephritis, there was a focal
increase in the mesangial FN-EIIIA+ intensity. In the severe
phase, the intensity of the mesangial staining was slightly higher.
The most important difference in this phase was that FN-EIIIA+
appeared in the Bowman's capsule and in association with cres-
cents (Fig. 8 D-F).
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EIIIB-FN. The EIIIB+ isoform was not detected in any renal thus play a role in the recruitment and trafficking of leukocytes in
structure either in controls or in rats with nephritis (not shown). the glomeruli, we characterized the glomerular infiltrates in the
V120-FIV. The V120-FN isoform was present in the mesangium mild and severe phases of nephritis by immunohistochemistry.
in a similar pattern to that of total FN and barely in the The number of OXI (leukocytes), W3/13 (T cells) and ED1
glomerular capillary loops. In the mild phase of nephritis the (monocytes!macrophages) positive cells was similar in control rats
distribution and intensity were similar. However, the intensity of and in animals with mild nephritis (Table 3). By contrast, in the
immunostaining in the severe phase was higher and it was clearly severe phase, an elevated number of OX1, ED1 and W3/13
detected on the outer side of the glomerular capillary loops (Fig. positive cells accumulated in the glomeruli, coinciding with the
8 G-I)5. maximal V120-FN in glomeruli. The infiltrates included mainly
Because V120-FN is a ligand for the VLA-4 integrin, and could monoeytes/macrophages and T lymphocytes. Ninety percent of
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Fig. 8. Immunolocalization of FN isofonns in immune complex prolifera-
tive nephritis. Total FN (A, B, C), EHIA-FN (D, E, F). and V120 (C, 11, 1)
staining in control rats (A, D, C). rats with mild nephritis (B, E. H) and
rats with severe nephritis (ci, H, I). Negative controls performed with
irrelevant antibodies arc also shown (J, K). See text for details. A-C and
J, indirect immunofluorescence xliii): D-1 and K. inimunoperoxidase
x 100.
Alonso et al: Fibronectin isoforms in immune complex nephritis 917
i . 8. Immunolocalization of FN isoforms in immune complex prolifera-
tive nephritis. Total  ( , , C), EIIIA-FN ( , , ), and V120 (G, H, I)
t  i  tr l r ts ( , , G), r ts it  il  ritis ( , , ) 
rats ith severe nephritis (G, , I). egative controls perfor ed ith
irr l t ti i s re ls  sho  (J, ). c text f r t ils. -  
J, indirect i unofluorescence X100; -T and , im unoperoxidase
100.
these cells have previously been shown to express the VLA-4
integrin [32j.
Discussion
In a rat model of progressive immune complex nephritis we
have analyzed for the first time the pattern of FN alternative
splicing, both at the mRNA and protein levels.
By ribonuclease protection assays using specific probes we
observed that glomeruli from control rats expressed all FN
mRNA isoforms, though in different proportions. In normal
glomeruli, approximately 40% of the FN mRNAs included the
EI1IA and V120 region, while the EII1B region was largely
excluded from mature mRNA (about 90%). However, there was
a shift in the pattern of alternative splicing of all FN mRNAs
isoforms, along the course of disease. So, while the proportion of
FN-EITIB+ mRNA versus total FN decreased, the relative values
of FN mRNAs containing the EIIIA and V120 regions increased
with the severity of the disease, indicating that a specific change in
the pattern of FN pre-mRNA alternative splicing happened
during the development of experimental ncphritis.
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Table 3. Glomerular infiltrate in immune complex proliferative
nephritis
N
Total
leukocytes T lymphocytes
Monocytes/
macrophages
Control 5 0.8 0.3 0.3 0.2 0.4 0.2
Mild 7 0.7 0.2 0.5 0.1 0.7 0.3
Severe 10 10.0 2.4a 3.1 0.8" 7.8 2.0"
Two sections per animal were stained with the MoAbs OX1 (against
leukocyte common antigen CD45, total leukocytes), W3/13 (CD43, T
leukocytes) and ED1 (rat monocytes/macrophages). Positive cells were
counted in twenty glomeruli by section. Data are expressed as positive
cells (mean SEM) by glomerular cross-section.
"P < 0.05 versus the control and mild phase groups.
Alterations in the expression of FN mRNA isoforms have also
been described in several settings, including wound healing [13],
intimal vascular thickening [141, cardiac hypertrophy [15, 16, 33],
and aortas from hypertensive rats [34]. However, the trend of
these changes was different depending on which pathology was
studied. For example, relative expression of both EIIIA and
EIIIB-FN mRNA increased in hormone-induced cardiac hyper-
trophy [33], while in aortas from hypertensive rats only a relative
increase in EIIIA-FN mRNA was found The meaning of
these findings is unknown, but these results probably indicate that
the regulation of FN pre-mRNA alternative splicing could depend
on the particular tissue and injury.
In addition, we studied by immunohistochemistry the different
FN isoforms. In agreement with previous reports, the FN-EIIIA+
protein was barely detected in the mesangium of control rats
[35—37]. In the mild phase of nephritis, this isoform increased in
the mesangium, while in the severe phase FN-EIIIA+ protein was
also detected, not only in the mesangium, but also in the
Bowman's capsule and crescents, suggesting that FN is synthe-
sized locally in these areas, probably by parietal and visceral
epithelial cells and/or macrophages. In this sense, cells in glomer-
ular crescents express FN mRNA [381.
FN-EIIIB+ protein was not detected in any renal structure of
the different experimental groups. In control glomeruli, only
about ten percent of total FN mRNA was EIIIB+. Thus, it is
possible that FN-EIIIB+ protein, if synthesized, may not be
detected by immunohistochemistry. In this sense, this isoform was
not present in normal human and rat kidney [18, 19, 37]. In the
mild and severe phases of nephritis there was a slight rise in the
FN-EIIIB+ mRNA steady-state levels (about 2-fold over con-
trol), which may not be sufficient to increase the concentration of
FN-EIIIB+ protein over the limits of detection.
In control rats, the FN-V120 isoform was present in the
mesangium and barely in the capillary loops. In the severe phase
of nephritis, the intensity of mesangial immunostaining increased
and it was clearly detected on the outer side of the glomerular
capillary loop. Although the FN-V120 isoform binds the integrin
VLA-4 [7, 8], its role in the normal glomeruli is unknown, since
VLA-4 is not expressed by intrinsic glomerular cells [39, 40].
Alternatively, this isoform could be a matrix support to the small
cell population of hone marrow-derived macrophages present in
normal glomeruli [41]. Moreover, FN-V120 could represent a
"receptive" extracellular matrix facilitating the adhesion and
trafficking of activated leukocytes during the remodeling and
injury processes. In this sense, both FN-V120 and infiltration by T
cells and macrophages peaked during the severe phase of nephri-
tis. Accordingly, the blockade of FN-V120/VLA-4 interaction
might represent a novel therapeutic approach. In this regard, the
administration of plasma FN to rats with immune complex
nephritis reduced the renal mononuclear cell infiltrates [25].
Although there is no clear explanation for this effect, we specu-
lated that the interaction of plasma FN, through the CS-I
sequence, with the VLA-4 positive leukocytes, may block the
adhesion to sites of glomerular injury. Thus, mimetic peptides of
the CS-i region may be useful in the treatment of nephritis. This
maneuver has been satisfactorily employed in the treatment of
rats with experimental arthritis [42]. To test this hypothesis, in vivo
experiments with CS-i peptides and defined FN fragments are
currently under way in our laboratory.
Although we have not completely defined the cells of origin for
the alternatively spliced FN mRNA during glomerular injury, it is
possible that both glomerular cells (endothelial, mesangial and
epithelial cells) and macrophages could participate in this process.
Glomerular cells could contribute mainly in the mild phase, in the
absence of cellular infiltrate, while macrophages could play a
major role in the severe phase. Further careful studies using in situ
hybridization are necessary to know the participation of the
different cells along the stages of the disease.
In conclusion, our data show that during glomerular injury
there was an up-regulation of EII1A and V120 FN isoforms. The
increment in the EIIIA isoform may be related to cell prolifera-
tion and migration. In particular, the increase in FN-V120 was
associated with glomerular infiltration by leukocytes. This sug-
gests that the adhesion of mononuclear cells to mesangial extra-
cellular matrix and glomerular capillary loop during the glomer-
ular injury may be mediated by VLA-4/FN-V120 interactions. The
blockade of the interaction between V120-FN and infiltrating
leukocytes may represent a new approach to the treatment of
nephritis.
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